GlaxoSmithKline agrees to settle *Relafen* antitrust litigation

London and Philadelphia, PA, February 6, 2004 - GlaxoSmithKline plc (GSK) today announced that it has agreed to settle a US antitrust case involving the nonsteroidal anti-inflammatory product *Relafen*. GSK will pay $175 million (£100 million) in settlement of a class action lawsuit brought on behalf of direct purchasers, including pharmaceutical wholesalers.* The settlement is being submitted for review today to the U.S. District Court for the District of Massachusetts, where the case has been pending since 2001. GSK continues to believe that its actions were appropriate in obtaining and enforcing its patent for *Relafen*.

Similar actions from other plaintiffs in the *Relafen* antitrust matter, including claims made by Teva, chain drug stores and Eon Labs have also been settled, resulting in further payments from GSK. There remains outstanding a claim from a class of indirect purchasers, including consumers, which is scheduled for trial in June 2004.

The company's financial results for Q4 2003, to be announced on 12th February, will include a legal charge of approximately £220 million, including provisions for both the settled and outstanding *Relafen* cases. Although this charge will adversely affect the company's earnings per share in the fourth quarter GSK's earnings guidance for 2003 remains high-single digit or better percentage growth in business performance earnings per share at constant exchange rates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information and a copy of the company's product development pipeline, visit GSK at [www.gsk.com](http://www.gsk.com).

**Cautionary statement regarding forward-looking statements**

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2002.

* Further details of the case are available in the company's 2002 Annual Report (page 106).

For more information:

GSK in focus | Reports and publications | GSK worldwide | Contact us | Site map | Terms and conditions | Accessibility | Your privacy

Updated February 06, 2004
© 2001-2006 GlaxoSmithKline - All rights reserved
GlaxoSmithKline agrees to settle <em>Relafen</em> antitrust litigation - GlaxoSmithKline

Enquiries
UK Media
- Martin Sutton 020 8047 5502
- David Mawdsley 020 8047 5502

US Media
- Nancy Pekarek (215) 751 7709
- Mary Anne Rhyne (919) 483 2839
- Patricia Seif (215) 751 7709

European Analyst/Investor
- Duncan Learmouth 020 8047 5540
- Philip Thomson 020 8047 5543
- Anita Kidgell 020 8047 5542

US Analyst/Investor
- Frank Murdolo (215) 751 7002
- Tom Curry (215) 751 5419

http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=137
8/16/2007